创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

靶向STING药物的研究进展

Advances in Drugs Targeting STING

  • 摘要: 固有免疫反应构成了宿主抵御病原体入侵的首道防线,在此过程中,环鸟苷酸-腺苷酸合酶(cyclic GMP-AMP synthase,cGAS)/干扰素基因刺激因子(stimulator of interferon gene,STING)通路发挥着核心作用。该通路不仅能够识别胞质中的双链DNA,进而触发固有免疫反应,还与抗肿瘤免疫、衰老进程、神经退行性疾病以及自身免疫病的发展存在紧密关联。综述近年来STING调控剂的研究进展,以及其在抗肿瘤疗法和自身免疫病治疗中的应用情况;探讨其在延缓衰老、治疗神经退行性疾病以及作为疫苗佐剂等方面的应用前景,旨在为靶向STING的药物研发提供参考依据。

     

    Abstract: The innate immune response acts as the first line of defense for the host against pathogen invasion. Throughout the process, the cyclic GMP-AMP synthase (cGAS) / stimulator of interferon gene (STING) pathway plays a central role. This pathway not only recognizes double-stranded DNA in the cytoplasm, thus triggering the innate immune response, but also has a close association with antitumor immunity, the aging process, neurodegenerative diseases, and the development of autoimmune diseases. This review summarizes the research progress of STING regulators in recent years, as well as their application in anti-tumor therapies and treatment of autoimmune diseases; it also explores the application prospects of STING regulators in delaying aging, treating neurodegenerative diseases, and serving as vaccine adjuvants, aiming to provide some reference for the research and development of drugs targeting STING.

     

/

返回文章
返回